National Healthcare Security Administration Issues 2026 National Medical Insurance Catalog Adjustment Work Plan 国家医保局发布2026年国家医保目录调整工作方案

The recent series of documents released by China's National Healthcare Security Administration signal a fundamental transformation in how the country's basic medical insurance catalog is adjusted—evolving from a "cost-control center" to a "market ecosystem shaper." The most notable aspect is not the refinement of traditional negotiation and renewal rules but the first systematic coordination between the "Commercial Health Insurance Innovative Drug Catalog" and the basic medical insurance catalog. This move transcends a simple expansion of catalogs; it marks a key integration of the payment mechanisms within a multi-tiered healthcare security framework.

On the surface, the 2026 plan appears to be a technical update, covering the entire process from application, negotiation, renewal, to competitive bidding. However, at its core, the policy's focus is subtly shifting. Previously, pharmaceutical companies’ primary anxiety centered almost entirely on securing a spot in the national medical insurance catalog—the "single entry ticket." Negotiations were essentially zero-sum games revolving around price and market access. Now, the introduction of the Commercial Health Insurance Innovative Drug Catalog effectively establishes a parallel, market-driven second channel. This means that innovative drugs with significant clinical value but prices that may exceed the current reimbursement capacity of basic medical insurance now have the potential to be included in a multi-tiered payment system. Pharmaceutical companies must adapt their strategies accordingly, needing to study both the "basic coverage" principle of social medical insurance and the "innovation inclusiveness" of the commercial insurance catalog—the latter clearly being more aligned with real-world market demands.

The continuation of the "Competitive Bidding Rules for Non-Exclusive Drugs" and the optimization of the "Renewal Rules for Negotiated Drugs" demonstrate a delicate balancing act between encouraging innovation and controlling fund expenditures. The competitive bidding rules aim to lower prices of generic and improved new drugs through market competition, thereby creating room for innovative drugs. The more closely watched renewal rules focus on stabilizing market expectations and avoiding the "insurance-driven price-cutting" that could dampen companies' enthusiasm for sustained R&D investment. A well-designed renewal mechanism should provide drugs already in the catalog with a reasonable market return period based on their performance, rather than subjecting them to annual uncertainties of price reductions. This essentially establishes a more sustainable payment environment for genuine, original innovation.

The core signal released by this policy combination is: The medical insurance authority is transitioning from a sole payer to a rule-setter and payment system integrator within the healthcare innovation ecosystem. Basic medical insurance covers fundamentals, while the commercial insurance catalog fosters innovation—only through their linkage can the pain points of "difficulty in hospital adoption and payment" for innovative drugs be truly resolved. For example, a cutting-edge cell therapy product might struggle to enter the basic medical insurance catalog but could gain a payment pathway through the commercial insurance catalog. Patients would gain access, pharmaceutical companies would receive returns, and the pressure on the medical insurance fund would be alleviated. This opens up policy space for segmentation and differentiated development in the pharmaceutical market.

Of course, this new blueprint also presents new challenges. The sustainable development of the Commercial Health Insurance Innovative Drug Catalog depends on whether a win-win payment loop can be formed among commercial insurers, pharmaceutical companies, healthcare institutions, and patients. How should pharmaceutical companies price products for the commercial insurance catalog? How can commercial insurers design attractive products? These questions require extensive market exploration within the policy framework. Nevertheless, the direction is clear: the 2026 policy toolbox is laying a broader and more diversified track for China's pharmaceutical innovation. It no longer focuses solely on the one-dimensional goal of "price reduction" but begins to build a more resilient healthcare payment ecosystem that can accommodate both "basic coverage" and "upgraded innovation." Future competition in the pharmaceutical market will not only be a contest of product strength but also a test of the ability to understand and navigate multi-tiered payment rules.

国家医保局最新发布的系列文件，标志着中国基本医保目录调整机制正从“成本控制中心”向“市场生态塑造者”发生深刻转变。其中最引人注目的，并非是对传统谈判与续约规则的细化，而是首次系统性地将“商业健康保险创新药品目录”与基本医保目录并列调整。这一举措，远不止是目录增加，更是对多层次医疗保障体系支付端的一次关键打通。

表面上看，2026年的方案是技术性更新，涉及申报、谈判、续约、竞价等全流程规则。但内核里，政策的重心正在发生微妙的迁移。过去，药企的核心焦虑几乎完全系于国家医保目录这张“单一入场券”，谈判就是一场围绕价格与准入的零和博弈。如今，商业健康保险创新药品目录的引入，实质上是在构建一条并行的、市场化的第二通道。这意味着，那些临床价值显著但价格可能超出基本医保当前支付能力的创新药，有了被纳入多层次支付体系的可能。药企的策略必须随之改变，需要同时研究基本医保的“保基本”原则和商保目录的“创新包容度”，后者显然更贴近真实世界的市场需求。

“非独家药品竞价规则”的延续与“谈判药品续约规则”的优化，则展现了在鼓励创新与控制基金支出之间精巧的平衡艺术。 竞价规则旨在通过市场竞争降低仿制药和改良型新药的价格，为创新药腾出空间。而更受关注的续约规则，其核心目标是稳定市场预期，避免“医保杀价”挫伤企业持续研发投入的积极性。一个设计良好的续约机制，应让已纳入目录、表现良好的药品获得合理的市场回报周期，而不是年年面临不确定的降价压力。这实质上是在为真正的源头创新建立更可持续的支付环境。

此次政策组合拳释放的核心信号是：医保部门正从单一的支付方，转变为医疗创新生态的规则制定者和支付体系的整合者。 基本医保保基本、商保目录促创新，二者联动才能真正化解创新药“进院难、支付难”的痛点。例如，一款前沿的细胞治疗产品，或许难以进入基本医保，但有望通过商保目录获得支付入口，患者可以使用，药企可以获得回报，医保基金的压力也得到分流。这为医药市场的细分和差异化发展打开了政策空间。

当然，新蓝图也意味着新挑战。商业健康保险目录的可持续发展，依赖于商保公司、药企、医疗机构和患者之间能否形成共赢的支付闭环。药企如何为商保目录产品定价？商保公司如何设计吸引人的产品？这些都需要市场在政策框架下进行大量探索。但从方向上看，这套2026年的政策工具箱，正试图为中国医药创新铺设一条更宽广、更多元的轨道。它不再仅仅关注于“降价”这一单向维度，而是开始着力构建一个能同时容纳“基础保障”与“升级创新”的、更具韧性的医疗支付生态。未来的医药市场竞争，将不仅是产品力的比拼，更是对多层次支付规则的理解与运营能力的较量。